1AEA:F:F-argenx SE (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 340

Change

-4.00 (-1.16)%

Market Cap

USD 20.34B

Volume

55.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

+3.50 (+3.04%)

USD 525.74B
VX1:F Vertex Pharmaceuticals Incorpo..

+3.50 (+0.93%)

USD 96.61B
RGO:F Regeneron Pharmaceuticals Inc

+14.20 (+1.61%)

USD 92.42B
CSJ:F CSL Limited

+2.56 (+1.52%)

USD 81.66B
CSJA:F CSL LTD SPON.ADR 2

+0.50 (+0.60%)

USD 78.61B
0QF:F Moderna Inc

+1.48 (+1.34%)

USD 44.82B
UNC0:F UCB S.A. UNSP.ADR 1/2

-1.00 (-1.67%)

USD 23.00B
UNC:F UCB SA

-0.90 (-0.75%)

USD 22.90B
1AE:F Argen-X

+2.20 (+0.61%)

USD 21.73B
22UA:F BioNTech SE

+0.40 (+0.47%)

USD 19.66B

ETFs Containing 1AEA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 20.34B 98% N/A 92% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector